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We previously presented 5-year survival analyses for all women in
Scotland diagnosed with breast cancer during 1987 (Twelves et al,
1998). That study demonstrated geographical variation in survival
that persisted even after adjustment for known prognostic factors.
This variability in survival appeared to be partly related to selec-
tion for surgery but also to differences in systemic adjuvant treat-
ment. In contrast to earlier findings, after adjustment for clinical
factors our data did not confirm a significant effect of surgical
specialization (Gillis and Hole, 1996), caseload (Sainsbury et al,
1995) or deprivation (Schrijvers et al, 1995; Karjalainen and
Pukkala, 1990) on survival. Here, we investigate whether our find-
ings are confirmed with follow-up beyond 10 years. 
PATIENTS AND METHODS 
Study population 
A national, population-based study of all women with invasive
breast cancer recorded by the Scottish Cancer Registry was under-
taken by the Scottish Cancer Therapy Network (SCTN). The
current study reports the 10-year survival of women diagnosed
with breast cancer in 1987 who had no evidence of metastases at
presentation and underwent surgery as part of their primary treat-
ment. 
Data collection and analysis 
All case notes were reviewed and information on referral patterns,
clinical characteristics, tumour pathology and primary treatment
extracted. Demographic data included age at diagnosis. Health
Board (HB; equivalent to the Health Authorities elsewhere in the
UK) of first treatment and the Carstairs deprivation index
(Carstairs and Morris, 1991). A further probability linkage
(Kendrick and Clarke, 1993) to the Registrar General’s death
records to the end of 1998 provided updated survival data. The
endpoint was death from any cause. Prior to undertaking these
analyses, a review of the database revealed small numerical differ-
ences. These do not substantially affect our main conclusions at 5
years, although the higher hazard ratio of death in Fife HB
compared with Greater Glasgow Health Board (GGHB) is no
longer significant. 
Kaplan-Meier univariate survival analyses were performed on
all clinical, treatment and service-related factors. Cox’s propor-
tional hazards multivariate analysis was then undertaken in two
models. One included clinical factors plus significant service-
related factors; the other included clinical factors and significant
treatment factors. 
RESULTS 
In all, 2581 patients were recorded with breast cancer in 1987; of
these, 135 were ineligible for analysis, most often because they
had in situ disease only. Case notes could not be located for a
further 252 patients and 79 cases were death certificate only regis-
trations, leaving 2115 (87%) potentially eligible patients available
for analysis. Another 175 patients with metastatic disease at
presentation and the 323 women who did not undergo definitive
surgery were also excluded, so 1617 women were included in this
study population. 
The overall Kaplan-Meier estimates of survival at 5 and 10
years for women with breast cancer diagnosed in 1987 were 70.9%
(95% CI: 68.7%, 73.1%) and 52.7% (50.3%, 55.1%), respectively.
In the univariate analyses all clinical factors (age, clinical stage,
oestrogen receptor status, pathological node status and patholog-
ical tumour size), service-related factors (HB, surgical caseload
and deprivation) and treatment factors (type of surgery and use of
adjuvant chemotherapy) that had been significant at 5 years
remained significant at 10 years (data not shown). 
In the multivariate analysis (Table 1), the clinical factors
retained significance (all P < 0.001). By contrast, treatment factors
were not significant at either 5 or 10 years. Amongst the service-
related factors, there was a trend for deprivation and surgical case-
load to be associated with poorer survival, but these remained
non-significant in the multivariate model with follow-up beyond
10 years. There was, however, significant variation in the risk of
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Table 1 Adjusted hazard ratios of death with a minimum of 6 and 11 years follow-up, from Cox regression 
Clinical factors Adjusted hazard of death (95% Cl) P value Adjusted hazard of death (95% Cl)  P value 
with deaths to end 1993 with deaths to end 1998
Age group (years) 0.0059a < 0.0001a
< 50 1.0 1.0 
50–64 1.02 (0.83, 1.27) 1.22 (1.01, 1.46) 
65–79 1.12 (0.90, 1.40) 1.50 (1.24, 1.81) 
> = 80 1.94 (1.35, 2.79) 2.81 (2.07, 3.81) 
Clinical stage 0.0003a 0.0003a
I 1.0 1.0 
II 1.45 (1.10, 1.92) 1.41 (1.13, 1.76) 
III 2.08 (1.48, 2.92) 1.85 (1.40, 2.46) 
Not known 1.58 (1.16, 2.16) 1.42 (1.11, 1.83) 
Oestrogen receptor status < 0.0001a < 0.0001a
Positive 1.0 1.0 
Negative 2.13 (1.71, 2.66) 1.86 (1.55, 2.23) 
Not known 1.42 (1.13, 1.79) 1.28 (1.06, 1.54) 
Node status by tumour size interaction < 0.0001a < 0.0001a
Node positive 
≤ 2 cm 4.70 (2.69, 8.23) 3.49 (2.34, 5.21) 
> 2 cm 5.23 (3.05, 8.95) 3.88 (2.65, 5.66) 
Not known 5.29 (2.95, 9.46) 3.74 (2.44, 5.74) 
Node INSb
≤ 2 cm 1.43 (0.73, 2.79) 1.22 (0.76, 1.97) 
> 2 cm 3.12 (1.70, 5.71) 2.26 (1.45, 3.53) 
Not known 2.18 (1.03, 4.61) 2.02 (1.18, 3.45) 
Node negativec
≤ 2 cm 1.0 1.0 
> 2 cm 3.29 (1.78, 6.07) 2.28 (1.45, 3.57) 
Not known 1.50 (0.65, 3.43) 0.91 (0.46, 1.81) 
Node not known 
≤ 2 cm 2.75 (1.55, 4.88) 2.21 (1.47, 3.32) 
> 2 cm 4.16 (2.34, 7.40) 3.01 (1.99, 4.57) 
Not known 3.77 (2.08, 6.81) 3.15 (2.05, 4.83) 
Service factors
Health Board 0.04a 0.0044a
Ayrshire and Arran 1.46 (1.06, 2.01) 1.50 (1.15, 1.96) 
Borders 1.24 (0.59, 2.59) 1.40 (0.80, 2.47) 
Argyll and Clyde 1.48 (1.05, 2.10) 1.43 (1.07, 1.90) 
Fife 1.30 (0.87, 1.93) 1.17 (0.84, 1.62) 
GGHB 1.0 1.0 
Highland 1.03 (0.65, 1.64) 0.96 (0.64, 1.42) 
Islandsd 0.66 (0.32, 1.39) 0.77 (0.43, 1.38) 
Lanarkshire 1.19 (0.85, 1.65) 1.12 (0.85, 1.47) 
Grampian 0.95 (0.69, 1.32) 0.96 (0.73, 1.25) 
Lothian 0.83 (0.61, 1.14) 0.79 (0.61, 1.02) 
Tayside 1.34 (0.95, 1.89) 1.19 (0.90, 1.59) 
Forth Valley 1.49 (0.95, 2.33) 1.31 (0.89, 1.92) 
Dumfries and Galloway 1.09 (0.69, 1.72) 0.93 (0.63, 1.38) 
Surgical caseloade 0.61f 0.18f
1–9 cases 1.07 (0.83, 1.37) 1.12 (0.91, 1.38) 
10–29 1.11 (0.91, 1.35) 1.17 (0.99, 1.38) 
Team  30 1.0 1.0 
Referral to oncologistg 0.21f 0.52f
Never/not primary 1.0 1.0 
Yes 1.12 (0.94, 1.34) 1.05 (0.91, 1.22) 
Deprivationh 0.28f 0.30f
Least deprived 1.0 1.0 
Intermediate 1.13 (0.92, 1.38) 1.05 (0.89, 1.24) 
Most deprived 1.24 (0.95, 1.61) 1.19 (0.95, 1.48) 
Treatment factors
Type of surgery 0.84f 0.32f
Mastectomy 1.0 1.0 
Breast conservation 0.98 (0.81, 1.19) 0.92 (0.78, 1.08) 
Adjuvant radiotherapy 0.83f 0.85f
Given 1.02 (0.85, 1.22) 0.99 (0.85, 1.15) 
Not given 1.0 1.0 
BJOC 01-1957 637-640  20/8/01  3:23 pm  Page 638death across the HBs at 5 years (P = 0.04). This effect was stronger
at 10 years (P = 0.004), with two HBs having a significantly higher
risk of death than GGHB. When the multivariate analyses were
extended to include survival of all 1940 women with non-
metastatic disease (i.e. the 1617 surgical, non-metastatic cases and
the 323 non-surgical cases, non-metastatic), at 5 years HB was of
borderline non-significance (P = 0.055); with 10 years follow-up
became statistically significant (P = 0.004) in this broader group.
Likewise, HB was also significant in a multivariate model limited
to breast cancer specific deaths (P = 0.003). 
DISCUSSION 
This study shows that the effect of the clinical factors on survival
remained significant with at least 10 years follow-up. More impor-
tantly, the proposition that HB affected survival at 5 years was
strengthened with longer follow-up. However, treatment factors
remained non-significant in the multivariate model, reflecting the
determination of treatment by clinical factors (e.g., patients with
poorer prognoses are more likely to receive chemotherapy). 
Previously, we were unable to demonstrate the beneficial effect
on survival of being managed by a higher caseload or specialist
surgeon (Sainsbury et al, 1995; Gillis and Hole, 1996) nor by being
resident in affluent areas (Schrijvers et al, 1995; Karjalainen and
Pukkala, 1990). Even with substantially more events (842
compared with 584) we still cannot substantiate those findings.
However, this study probably has insufficient power to exclude a
potentially important effect of deprivation (Thomson et al, 2001)
or case load on survival. 
The effect of HB on survival was of borderline significance at 5
years, but at 10 years it is clear and statistically significant (P =
0.004). In the multivariate models, adjusted survival across HBs
ranged from 67% to 84% at 5 years and 43% to 65% at 10 years. The
reason for this effect of HB remains unclear. It is not easily attributed
to differences in the distributions of clinical factors across the HBs
because these have been incorporated in the multivariate model.
Similarly, differences in survival persist when only breast cancer
specific deaths were considered, suggesting that the risk of a non-
breast cancer death was similar across the HBs. The proportions of
women who had non-metastatic disease, but did not undergo defini-
tive surgery, varied widely between HBs (range 6.2–31.0%). With 5-
year follow-up there appeared to be selection bias due to surgery
since HB was an independent predictor of outcome only if the
analysis was limited to surgical patients. However, at 10 years this
bias was not seen and HB had an independent effect on survival in
all non-metastatic patients irrespective of whether they underwent
definitive surgery. 
The apparently strengthened effect of HB on survival is,
however, compatible with geographical differences in the use of
adjuvant systemic therapy as the Early Breast Cancer Trialists’
Collaborative Group (EBCTCG) overview showed that survival
curves typically diverge with time in adjuvant trials (EBCTCG,
1992). Although adjuvant systemic treatment appeared not to
influence outcome in the multivariate model, this can be explained
by the nature of the disease determining such treatment. Moreover,
the overview hypothecated a 6% survival benefit at 10 years
(EBCTCG, 1992) and, despite the additional events, the current
study still has only approximately 35% power to detect an effect of
this magnitude. 
Further follow-up confirms that, historically at least, the HB of
their treatment was an important determinant of survival in women
with breast cancer. The most likely explanation is differences in
adjuvant systemic (EBCTCG, 1992) or local (EBCTCG, 2000)
treatment between HBs. Indeed, this may explain the apparent
effect of surgical caseload and specialization previously described
(Sainsbury et al, 1995; Gillis and Hole, 1996). Interest now lies in
whether this effect of HB remains in women diagnosed more
recently, when the use of adjuvant systemic treatment appeared
uniform across the HBs (Scottish Breast Cancer Focus Group,
1996). 
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Table 1 Contiinued
Treatment factors Adjusted hazard of death (95% Cl) P value Adjusted hazard of death (95% Cl)  P value 
with deaths to end 1993 with deaths to end 1998
Adjuvant chemotherapy 0.92f 0.53f
Given 0.98 (0.72, 1.34) 1.09 (0.83, 1.42) 
Not given 1.0 1.0 
Adjuvant endocrine therapy 0.43f 0.16f
Given 0.93 (0.77, 1.12) 0.89 (0.76, 1.05) 
Not given 1.0 1.0 
Adjuvant chemotherapy or endocrine therapy 0.28f 0.15f
Given 0.90 (0.74, 1.09) 0.89 (0.76, 1.04) 
Not given 1.0 1.0 
aP Values are Wald statistics for entry, adjusted for all other significant factors; bINS=inadequate negative sample = 1, 2, 3, unknown number taken, all negative;
cNegative = 4 or more nodes taken, all negative; dDue to the small numbers of cases, the Orkney, Shetland  and Western Isles Health Boards were analysed
together as a single group, representing off-mainland care; eNote that the 12 cases where the surgeon was unknown were not included in the analysis; 
fP values are Wald statistics for entry, adjusted for significant clinical factors only; gNote that the 29 cases where the date of referral to the oncologist was
unknown were not included in the analyses because it was not possible to determine whether or not this was part of primary treatment; hNote that a deprivation
score could not be assigned for one case.
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